Liu S - Search Results

1

Collaborative studies on the development of national reference standards for potency determination of H7N9 influenza vaccine.

Li C, Xu K, Hashem A, Shao M, Liu S, Zou Y, Gao Q, Zhang Y, Yuan L, Xu M, Li X, Wang J. Li C, et al. Among authors: liu s. Hum Vaccin Immunother. 2015;11(6):1351-6. doi: 10.1080/21645515.2015.1032490. Hum Vaccin Immunother. 2015. PMID: 25970793 Free PMC article.

2

Safety and immunogenicity of adjuvanted inactivated split-virion and whole-virion influenza A (H5N1) vaccines in children: a phase I-II randomized trial.

Wu J, Liu SZ, Dong SS, Dong XP, Zhang WL, Lu M, Li CG, Zhou JC, Fang HH, Liu Y, Liu LY, Qiu YZ, Gao Q, Zhang XM, Chen JT, Zhong X, Yin WD, Feng ZJ. Wu J, et al. Vaccine. 2010 Aug 31;28(38):6221-7. doi: 10.1016/j.vaccine.2010.07.008. Epub 2010 Jul 16. Vaccine. 2010. PMID: 20638454 Clinical Trial.

3

Immunogenicity and safety of a trivalent inactivated influenza vaccine produced in Shenzhen, China.

Mo Z, Nong Y, Liu S, Shao M, Liao X, Go K, Lavis N. Mo Z, et al. Among authors: liu s. Hum Vaccin Immunother. 2017 Jun 3;13(6):1-7. doi: 10.1080/21645515.2017.1285475. Epub 2017 Feb 14. Hum Vaccin Immunother. 2017. PMID: 28301266 Free PMC article. Clinical Trial.

4

A neuraminidase activity-based microneutralization assay for evaluating antibody responses to influenza H5 and H7 vaccines.

Zhao H, Xu K, Jiang Z, Shao M, Liu S, Li X, Wang J, Li C. Zhao H, et al. Among authors: liu s. PLoS One. 2018 Nov 15;13(11):e0207431. doi: 10.1371/journal.pone.0207431. eCollection 2018. PLoS One. 2018. PMID: 30440054 Free PMC article.

5

Immunogenicity and safety of a trivalent inactivated influenza vaccine produced in Shenzhen, China versus a comparator influenza vaccine: a phase IV randomized study.

Hu Y, Chu K, Lavis N, Li X, Liang B, Liu S, Shao M, Shu JD, Tabar C, Samson S. Hu Y, et al. Among authors: liu s. Hum Vaccin Immunother. 2019;15(5):1066-1069. doi: 10.1080/21645515.2019.1581541. Epub 2019 Apr 2. Hum Vaccin Immunother. 2019. PMID: 30779689 Free PMC article. Clinical Trial.

6

Immunological non-inferiority and safety of a quadrivalent inactivated influenza vaccine versus two trivalent inactivated influenza vaccines in China: Results from two studies.

Liu X, Park J, Xia S, Liang B, Yang S, Wang Y, Syrkina O, Lavis N, Liu S, Zhao C, Ding J, Hu J, Samson SI, de Bruijn IA; FSQ01 and FSQ02 Study Groups. Liu X, et al. Among authors: liu s. Hum Vaccin Immunother. 2022 Nov 30;18(6):2132798. doi: 10.1080/21645515.2022.2132798. Epub 2022 Nov 3. Hum Vaccin Immunother. 2022. PMID: 36328438 Free PMC article. Clinical Trial.

7

Influenza virus vaccine expressing fusion and attachment protein epitopes of respiratory syncytial virus induces protective antibodies in BALB/c mice.

Bian C, Liu S, Liu N, Zhang G, Xing L, Song Y, Duan Y, Gu H, Zhou Y, Zhang P, Li Z, Zhang K, Wang Z, Zhang S, Wang X, Yang P. Bian C, et al. Among authors: liu n, liu s. Antiviral Res. 2014 Apr;104:110-7. doi: 10.1016/j.antiviral.2014.01.022. Epub 2014 Feb 6. Antiviral Res. 2014. PMID: 24509239

8

Immunogenicity and safety of an inactivated quadrivalent influenza vaccine candidate versus inactivated trivalent influenza vaccines in participants >/=3 years of age: a double-blind, randomized, parallel-controlled phase III clinical trial in China.

Wang SY, Liu SZ, Chu K, Zhao Y, Zhu FC, Hu YM, Meng FY, Li JX, Luo L, Yang JY, Liu P, Yu J. Wang SY, et al. Expert Rev Vaccines. 2017 Nov;16(11):1155-1169. doi: 10.1080/14760584.2017.1374181. Epub 2017 Sep 18. Expert Rev Vaccines. 2017. PMID: 28870140 Free article. Clinical Trial.

9

Application of low-intensity anticoagulation after On-X mechanical aortic valve replacement.

Zou K, Wei D, Xiang B, Yu T, Huang K, Liu S. Zou K, et al. Among authors: liu s. J Cardiothorac Surg. 2025 Jan 9;20(1):49. doi: 10.1186/s13019-024-03215-7. J Cardiothorac Surg. 2025. PMID: 39780165

10

Chitosan/Alginate-Based Hydrogel Loaded With VE-Cadherin/FGF as Scaffolds for Wound Repair in Different Degrees of Skin Burns.

Liu S, Wei L, Huang J, Luo J, Weng Y, Chen J. Liu S, et al. J Biomed Mater Res B Appl Biomater. 2025 Jan;113(1):e35533. doi: 10.1002/jbm.b.35533. J Biomed Mater Res B Appl Biomater. 2025. PMID: 39780026

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

77,855 results

Search Page

Filters